We are breaking new ground in the treatment of metabolic diseases
Media Release
May 05, 2026
Our poster entitled «Changing Paradigm in Pancreatic Enzyme Replacement Therapy: Towards Once-a-Day Dose» has been recognized with a Poster of Distinction Award at Digestive Disease Week (DDW) in Chicago.
February 28, 2026
Our CEO, Dr. Yves Dudal and our translational expert, Dr. Kristen Skvorak represented Perseo at the National PKU Alliance Scientific Conference in New Orleans, on Rare Disease Day.
We are breaking new ground in the treatment of digestive diseases
At Perseo pharma our goal is to develop oral enzyme therapies to help patients suffering from digestive diseases
Many people around the world suffer from digestive deficiencies. The cause can be a defective pancreas (exocrine pancreatic insufficiency derived from cystic fibrosis, pancreatitis, pancreatic cancer, and other related diseases) or the consequences of a severe medical treatment (chemotherapy, antibiotics).
Current treatments include oral enzyme therapies. Often, those medicines lack efficiency as enzymes are fragile and once ingested, can quickly lose activity in the harsh gastrointestinal environment. Also, they are rapidly flushed down the GI tract together with food and liquids. What patients must endure is a real pill burden, having to take multiple pills (up to 20) per day and at the same time, due to the rapid flushing, they lose the vital nutrition.
This is where Perseo pharma, a preclinical stage biopharmaceutical company, comes in. We are on the quest to breaking new ground in enzyme therapies. Our goal is to develop a series of innovative patient-centered oral enzyme digestive therapies based on our proprietary nanotechnology platform. The platform can be applied to any enzyme or cocktail of enzymes. This innovative technology protects the enzyme in a nano-shield and binds it specifically to the mucus of the small intestine, where the digestion takes place. Digestion efficiency can therefore be highly improved while the pill burden can be eliminated.
Our pipeline
| Therapeutic indication | Therapeutic enzyme(s) | Development stage |
| Wave 1 – Digestive therapies |
|---|
| PER301 | Exocrine Pancreatic Insufficiency (EPI) | Pancreatic Enzyme Replacement Therapy (PERT) with cocktail of lipase, protease, amylase | Preclinical (FiH 2025)  |
| PER3N2 | Carbohydrate Malabsorption | ||
| PER303 | Phenylketonuria (PKU) | Phenylalanine Ammonia Lyase |  |
| PER312 | Congenital Sucrase-Isomaltase Deficiency (CSID) | ||
| PER304 | Maple Syrup Urine Disease (MSUD) | Confidential | Preclinical |
| Wave 2 – Other therapeutic areas |
|---|
| PER200 | Lysosomal Storage Diseases | Systemic enzyme replacement therapies | Research |
*FiH: First in Human